MX2016011862A - Inhibidores de c5a para el tratamiento de la neumonia viral. - Google Patents
Inhibidores de c5a para el tratamiento de la neumonia viral.Info
- Publication number
- MX2016011862A MX2016011862A MX2016011862A MX2016011862A MX2016011862A MX 2016011862 A MX2016011862 A MX 2016011862A MX 2016011862 A MX2016011862 A MX 2016011862A MX 2016011862 A MX2016011862 A MX 2016011862A MX 2016011862 A MX2016011862 A MX 2016011862A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- pneumonia
- inhibitors
- viral pneumonia
- relates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a inhibidores de C5a para uso en el tratamiento de la neumonía, especialmente de la neumonía viral. La invención también se refiere al uso de inhibidores de C5a en la preparación de una composición farmacéutica para el tratamiento de la neumonía, especialmente de la neumonía viral. Los inventores se refieren además a métodos para el tratamiento de la neumonía, especialmente de la neumonía viral, que comprenden la etapa de administrar una cantidad terapéutica de un inhibidor de C5a a un sujeto en necesidad del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14160947 | 2014-03-20 | ||
| PCT/EP2015/055947 WO2015140304A1 (en) | 2014-03-20 | 2015-03-20 | Inhibitors of c5a for the treatment of viral pneumonia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016011862A true MX2016011862A (es) | 2016-12-05 |
Family
ID=50342223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016011862A MX2016011862A (es) | 2014-03-20 | 2015-03-20 | Inhibidores de c5a para el tratamiento de la neumonia viral. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10227397B2 (es) |
| EP (1) | EP3119802B1 (es) |
| JP (2) | JP6718379B2 (es) |
| KR (1) | KR20160127042A (es) |
| CN (2) | CN106132982A (es) |
| AU (1) | AU2015233380A1 (es) |
| BR (1) | BR112016021629A2 (es) |
| CA (1) | CA2940319A1 (es) |
| CL (1) | CL2016002255A1 (es) |
| EA (1) | EA201691481A1 (es) |
| IL (1) | IL247364A0 (es) |
| MX (1) | MX2016011862A (es) |
| PH (1) | PH12016501830A1 (es) |
| SG (1) | SG11201607740TA (es) |
| WO (1) | WO2015140304A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201914111XA (en) | 2014-03-20 | 2020-03-30 | Samumed Llc | 5-substituted indazole-3-carboxamides and preparation and use thereof |
| US10227397B2 (en) | 2014-03-20 | 2019-03-12 | Inflarx Gmbh | Inhibitors of C5a for the treatment of viral pneumonia |
| DK3154561T3 (da) | 2014-06-12 | 2019-10-07 | Ra Pharmaceuticals Inc | Modulering af komplementaktivitet |
| LT3250230T (lt) | 2015-01-28 | 2021-12-27 | Ra Pharmaceuticals, Inc. | Komplemento aktyvumo moduliatoriai |
| SG11201804721SA (en) | 2015-12-16 | 2018-07-30 | Ra Pharmaceuticals Inc | Modulators of complement activity |
| CN109310760A (zh) | 2016-06-07 | 2019-02-05 | 诺华股份有限公司 | 抗c5抗体给药方案 |
| MA45235A (fr) | 2016-06-14 | 2019-04-17 | Regeneron Pharma | Anticorps anti-c5 et leurs utilisations |
| JP7301741B2 (ja) | 2016-12-07 | 2023-07-03 | ラ ファーマシューティカルズ インコーポレイテッド | 補体活性のモジュレータ |
| US10376595B2 (en) * | 2017-04-03 | 2019-08-13 | Inflarx Gmbh | Treatment of inflammatory diseases with inhibitors of C5a activity |
| AU2018249310A1 (en) | 2017-04-03 | 2019-10-17 | Inflarx Gmbh | Treatment of inflammatory diseases with inhibitors of C5a activity |
| WO2018234118A1 (en) | 2017-06-23 | 2018-12-27 | Inflarx Gmbh | TREATMENT OF INFLAMMATORY DISEASES BY INHIBITORS OF C5A ACTIVITY |
| EP3724226A1 (en) | 2017-12-13 | 2020-10-21 | Regeneron Pharmaceuticals, Inc. | Anti-c5 antibody combinations and uses thereof |
| KR20220047826A (ko) | 2019-08-16 | 2022-04-19 | 리제너론 파마슈티칼스 인코포레이티드 | 고 농도의 항-c5 제형 |
| BR112022019090A2 (pt) * | 2020-03-27 | 2022-11-08 | Inflarx Gmbh | Inibidores de c5a para o tratamento de infecção por coronavírus |
| TW202208427A (zh) | 2020-05-06 | 2022-03-01 | 德商因夫萊亞斯有限公司 | 人源化抗ｃ５ａ抗體 |
| WO2023077053A2 (en) | 2021-10-28 | 2023-05-04 | Regeneron Pharmaceuticals, Inc. | Crispr/cas-related methods and compositions for knocking out c5 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1425042B2 (en) * | 2001-08-17 | 2016-02-10 | Genentech, Inc. | Complement pathway inhibitors binding to c5 and c5a without preventing the formation of c5b |
| EP2371861B1 (en) * | 2002-01-25 | 2017-08-09 | Novo Nordisk A/S | Monoclonal antibodies against extracellular loops of C5aR |
| EP2327725A1 (en) * | 2009-11-26 | 2011-06-01 | InflaRx GmbH | Anti-C5a binding moieties with high blocking activity |
| AU2011204483B2 (en) * | 2010-01-08 | 2016-02-11 | Volution Immuno Pharmaceuticals Sa | EV576 for use in the treatment of viral infections of the respiratory tract |
| SI2563813T1 (sl) | 2010-04-30 | 2015-12-31 | Alexion Pharmaceuticals, Inc. | Protitelesa anti-C5A in postopki uporabe protiteles |
| CN106397584A (zh) * | 2010-06-17 | 2017-02-15 | 特瑞利斯生物科学有限责任公司 | 可用于被动流感免疫的抗体 |
| US10227397B2 (en) | 2014-03-20 | 2019-03-12 | Inflarx Gmbh | Inhibitors of C5a for the treatment of viral pneumonia |
-
2015
- 2015-03-20 US US15/127,676 patent/US10227397B2/en active Active
- 2015-03-20 KR KR1020167025906A patent/KR20160127042A/ko not_active Application Discontinuation
- 2015-03-20 CN CN201580014552.0A patent/CN106132982A/zh active Pending
- 2015-03-20 BR BR112016021629A patent/BR112016021629A2/pt not_active Application Discontinuation
- 2015-03-20 MX MX2016011862A patent/MX2016011862A/es unknown
- 2015-03-20 CA CA2940319A patent/CA2940319A1/en not_active Abandoned
- 2015-03-20 JP JP2016558056A patent/JP6718379B2/ja active Active
- 2015-03-20 WO PCT/EP2015/055947 patent/WO2015140304A1/en active Application Filing
- 2015-03-20 AU AU2015233380A patent/AU2015233380A1/en not_active Abandoned
- 2015-03-20 SG SG11201607740TA patent/SG11201607740TA/en unknown
- 2015-03-20 EP EP15711177.4A patent/EP3119802B1/en active Active
- 2015-03-20 CN CN202310453303.8A patent/CN116785426A/zh active Pending
- 2015-03-20 EA EA201691481A patent/EA201691481A1/ru unknown
-
2016
- 2016-08-18 IL IL247364A patent/IL247364A0/en unknown
- 2016-09-06 CL CL2016002255A patent/CL2016002255A1/es unknown
- 2016-09-19 PH PH12016501830A patent/PH12016501830A1/en unknown
-
2019
- 2019-01-24 US US16/256,100 patent/US10858421B2/en active Active
-
2020
- 2020-04-16 JP JP2020073194A patent/JP7041708B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020125324A (ja) | 2020-08-20 |
| EP3119802B1 (en) | 2019-12-04 |
| JP7041708B2 (ja) | 2022-03-24 |
| WO2015140304A1 (en) | 2015-09-24 |
| SG11201607740TA (en) | 2016-10-28 |
| BR112016021629A2 (pt) | 2018-07-10 |
| CN116785426A (zh) | 2023-09-22 |
| US10227397B2 (en) | 2019-03-12 |
| JP2017514791A (ja) | 2017-06-08 |
| KR20160127042A (ko) | 2016-11-02 |
| PH12016501830A1 (en) | 2016-11-21 |
| CA2940319A1 (en) | 2015-09-24 |
| IL247364A0 (en) | 2016-11-30 |
| EP3119802A1 (en) | 2017-01-25 |
| CN106132982A (zh) | 2016-11-16 |
| US20170137499A1 (en) | 2017-05-18 |
| US10858421B2 (en) | 2020-12-08 |
| EA201691481A1 (ru) | 2017-02-28 |
| CL2016002255A1 (es) | 2017-08-25 |
| US20190202900A1 (en) | 2019-07-04 |
| JP6718379B2 (ja) | 2020-07-08 |
| AU2015233380A1 (en) | 2016-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016501830A1 (en) | Inhibitors of c5a for the treatment of viral pneumonia | |
| MX2023008693A (es) | Polinucleotidos moduladores. | |
| TW201613901A (en) | New compounds | |
| MX2020009780A (es) | Compuestos de inhibidor de autotaxina. | |
| MY187540A (en) | Compounds active towards bromodomains | |
| PH12016500094A1 (en) | Autotaxin inhibitors | |
| PH12016502291A1 (en) | Indolizine derivatives as phosphoinositide 3-kinases inhibitors | |
| MX2017002816A (es) | Derivados de pirazolopiridina y su uso en terapia. | |
| MD20170048A2 (ro) | Formulare pe bază de acetat de abirateronă şi procedee de utilizare a acesteia | |
| MX2015016741A (es) | Inhibidores de pi3 cinasa delta y gama selectivos duales. | |
| MX2017004808A (es) | Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple. | |
| IN2014MU00303A (es) | ||
| PH12016502530A1 (en) | Pharmaceutical compositions comprising dgla and use of same | |
| MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
| MX2020009444A (es) | Composicion farmaceutica oral de isotretinoina con dosis baja y su proceso de preparacion. | |
| PH12016501686A1 (en) | Pharmaceutical compositions of sitagliptin | |
| PH12017500459A1 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
| PH12017500348B1 (en) | Tetrahydroquinoline derivatives as bromodomain inhibitors | |
| IN2014CH00840A (es) | ||
| IN2014MU00916A (es) | ||
| PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
| IN2014CH01391A (es) | ||
| PH12020500472A1 (en) | Autotaxin inhibitor compounds | |
| MX2017005669A (es) | Derivados de hidroxido de bencilo, preparacion de los mismos y uso terapeutico de los mismos. | |
| MX2017001512A (es) | Compuestos activos hacia bromodominios. |